Eli Lilly and Company (LLY)vsPulsenmore Ltd. Ordinary Shares (PLSM)
LLY
Eli Lilly and Company
$1,185.71
-0.52%
HEALTHCARE · Cap: $1.02T
PLSM
Pulsenmore Ltd. Ordinary Shares
$3.31
-3.50%
HEALTHCARE · Cap: $22.17M
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs -39.6%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
PLSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Revenue surging 578.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 34.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 0.0%
ROE of -31.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : PLSM
The strongest argument for PLSM centers on Revenue Growth, Debt/Equity. Revenue growth of 578.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, P/E Ratio, Debt/Equity.
Bear Case : PLSM
The primary concerns for PLSM are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while PLSM is a hypergrowth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.51 — expect wider price swings.
PLSM is growing revenue faster at 578.0% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 39/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Pulsenmore Ltd. Ordinary Shares
HEALTHCARE · MEDICAL DEVICES · USA
Pulsenmore Ltd. engages in the provision of self-scan ultrasound devices for remote clinical diagnosis and screening in Israel and Europe. The company is headquartered in Omer, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?